IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) concerning possible violations of federal securities laws.
If you purchased shares of Abbott and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
On April 28, 2016, Abbott announced a definitive agreement to acquire St. Jude Medical Inc. (“St. Jude”). On October 11, 2016, St. Jude issued a warning to physicians and patients that batteries on thousands of its implantable defibrillators can quickly and unexpectedly deplete. Two people died after their devices failed to work correctly because of the drained battery, while 47 others reported dizziness or fainting. The warning applied to devices made before May 2015, which are in use by approximately 350,000 people worldwide. Abbott stated that it still expects to close its acquisition of St. Jude by the end of 2016.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.